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a b s t r a c t
Introduction: Fibroblast growth factor 23 (FGF23) is a key regulator in phosphate and vitamin
D metabolism When measured with c-terminal assay, it has been shown to be increased
following burn. Progress in understanding FGF23 physiology has emphasized the impor-
tance of assessing the intact form of FGF23.
Methods: The present cohort study is a complementary analysis of a previously published
work. Patients >18 years, admitted within 24 h after injury with burn surface area (BSA)
>10% were included. C-terminal (c-term) and intact (i) FGF23 assay were performed at
admission and every week during 4 weeks of follow-up. Inflammation and iron status were
assessed at the same time points.
Results: Twenty patients were initially included and 12 were followed until day 28. The
c-term FGF23 tended to gradually increase during the 4 weeks of follow-up while iFGF23 was
quite stable into normal ranges. Iron status showed a typical inflammatory profile. C-term
FGF23 was significantly positively correlated with c-reactive protein (CRP) and negatively
correlated with iron levels. iFGF23 was not correlated with CRP or iron.
Conclusion: FGF23 status following burn is characterized by a dissociation between c-term
FGF23 and iFGF23. The hypothesis of an increased cleavage may be raised. Respective role of
inflammation and iron levels in such deregulation need to be specified. Both c-term and
intact assays should be performed in further studies aiming to increase knowledge on FGF23
regulation and effects in burn patients.
# 2016 Elsevier Ltd and ISBI. All rights reserved.
Available online at www.sciencedirect.com
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Fibroblast growth factor 23 (FGF23) is a bone derived hormone
that is implicated in phosphate (P) and vitamin D (VD)* Corresponding author at: Burn Centre and General Intensive Care 
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0305-4179/# 2016 Elsevier Ltd and ISBI. All rights reserved.regulation. It is produced mainly by osteocytes, but also by
osteoblasts, osteoprogenitor cells, cementoblasts, odonto-
blasts, and chondrocytes [1]. FGF23 binds the FGF receptor –
aKlotho complex. FGF receptor (FGFR) is broadly expressed,
while the co-receptor aKlotho is expressed only in a fewDepartment, University Hospital, Sart-Tilman B35, B-4000 Lie`ge,
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target of FGF23 is the kidney where it regulates genes of 2a
sodium/phosphate cotransporter and 1a-hydroxylase, leading
to phosphate excretion and inhibition of 25 hydroxyvitamin D
(25(OH)-D) hydroxylation [2]. In addition, FGF23 is able to
stimulate expression of the vitamin D 24-hydroxylase, thus
increasing 25(OH)-D and 1,25 dihydroxyvitamin D (1,25(OH)2-
D) inactivation. The principal regulators of FGF23 are thought
to be P and 1,25(OH)2-D levels. However, the regulation of
FGF23 expression is complex and still incompletely under-
stood.
Burn induces significant physiologic changes involving
cardiovascular system, immune system, metabolism or
electrolyte balance. In particular, severe hypophosphatemia
is frequently observed in acute burn patients. The exact
mechanism of this phenomenon is not fully known but
probably involves various factors such as type and quantity of
fluid resuscitation, acid-base disturbances, electrolytes imbal-
ances catecholamines or exudative losses [3,4]. Hypopho-
sphatemia may have significant consequences in term of
cellular membrane integrity or energy metabolism. From
another point of view, burn has repercussions on VD synthesis
due to skin damage and, later, strategies to prevent abnormal
scarring following burn healing (sunlight eviction and pres-
sure garments). Furthermore, alterations of VD physiology and
metabolism may be suspected in severe burn patients who are
thus at high risk of VD deficiency [5]. Given its role in P and VD
metabolism, it may be therefore relevant to focus on FGF23 in
the particular context of burn.
In a previous work [6], we studied blood levels of c-
terminal FGF23 (c-term FGF23) in adult burn patients during
acute care. However, FGF23 status may be even more complex
than reported, due to the processing of the FGF23 protein
(Fig. 1). FGF23 is initially expressed as a 251-amino acid
protein. The signal peptide (the 24 first amino acids) is then
cleaved off to produce the mature protein, which is consid-
ered biologically active. This last molecule is secreted intact
or cleaved within bone cells. The proteolytic cleavage site is
located between amino acid 179 and 180 (the RXXR region)
and is thought to be recognized by subtilisin-like protein
convertases such as furin. Cleavage results in production of
the two inactive N-terminal and C-terminal fragments.Fig. 1 – Processing o
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nyltransferase 3 (GALNT3) seems to prevent cleavage [2].
There are currently two strategies to quantify circulating
FGF23 concentrations, detecting different hormone’s forms.
The c-term enzyme-linked immunosorbent assay (ELISA)
recognizes both intact hormone and C-terminal fragment,
while the intact ELISA only recognizes the full-length mature
hormone (Fig. 1).
In the past few years, knowledge about FGF23 physiology,
processing and regulation has improved. Particularly, impact
of iron deficiency on FGF23 production and cleavage has been
cited in different clinical conditions [2,7]. Moreover, new
commercial intact assays were recently available at more
affordable terms. Using frozen blood samples from adult burn
patients included in our previous study [6], the objective of the
present analyses was to explore intact FGF23 in conjunction
with iron and inflammation status. Indeed, data about
intact FGF23 have not yet been reported in the specific
context of burn.
2. Methods
This cohort study was conducted from March 2012 to January
2013 in a 6-bed burn unit after approval by the local Ethics
Committee of our University Hospital (Ref B707201213417, 6th
March 2012). Informed consent was obtained from the
patients or their relatives prior to enrolment.
The details of the study design have been previously
published [6]. In summary, Caucasian patients over 18 years,
with a burn surface area (BSA) greater than 10% and admitted
within the first 24 h following injury were included. Pregnan-
cy, renal or liver failure, prior vitamin D substitution were
considered exclusion criteria. They benefited from local
standard monitoring and care procedures in term of fluid
resuscitation, nutrition and surgery. They daily received
vitamin D3 (cholecalciferol, VD3) from nutrition and multivi-
tamin complex supplementation, reaching a daily dose of 600
to 800 UI. Patients did not receive any iron supplementation.
Iron intakes ranged around 20 mg per day, provided by
hospital made menu, enteral nutrition (Fresubin1 HP Energy,
Fresenius-Kabi, Germany), oral nutritional supplementsf FGF23 protein.
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fibres, Nestle, Switzerland) or micronutrient complex (Supra-
dyn1 Energy, Bayer, Germany). A restrictive and individual-
ized strategy was applied for red blood cell (RBC) transfusion.
Blood samples were collected at admission (D0) and then
every week during the first month of in-hospital follow-up.
Blood was notably drawn in serum gel tube (Venosafe Plastic
Tubes, Terumo, Haasrode, Belgium) before being centrifugated
(3500 rpm, 15 min, 4 8C). Supernatant was finally frozen and
stored at 80 8C. Similarly, blood was also drawn in lithium
heparin gel tube.
C-term and intact FGF23 concentrations were determined
with ELISA method (Immunotopics1, Immunotopics Interna-
tional, San Clemente, CA, USA). Normal ranges were respec-
tively 30–176 RU/ml and 8.6–72.8 pg/ml. In our lab, the
coefficient of variation of both assays was <10%. Creatinine,
phosphate and C-reactive protein (CRP) blood concentrations
were determined with Cobas1 automate (Roche, Mannheim,
Germany). 1,25(OH)2-D was assayed with iSYS
1 automate
(IDS, Boldon, UK). Iron status was assessed using the same
automate. Iron, ferritin and transferrin were measured using
spectrophotometric assay, chemiluminescence immunoassay
and immunoturbidimetric assay, respectively. Serum trans-
ferrin saturation (TSAT) was calculated using the following
formula: TSAT = iron (mmol/l)/[transferrin (g/l)  25].
Urine samples were collected at the same time as blood
samples. Urine levels of phosphate was assayed with Cobas1
automate (Roche, Mannheim, Germany). The fractional
excretion (FE) of phosphate was calculated according to the
following equation: FE P = (urine P  plasma creatinine)/
(plasma P  urine creatinine)  100.
Statistical analysis was performed using Graphpad Prism
(version 6.0 for Mac OSX, Graphpad Inc., San Diego, CA, USA).
Data were tested for normality using the Shapiro–Wilk test.
Results are expressed as medians and ranges (min–max).
Paired data (at D0 and D28 for the 12 patients who completed
the study) were compared using Wilcoxon test. Unpaired data
were compared using Mann–Whitney test. Proportions were
compared using Fisher’s exact test. Correlations were assessed
using nonparametric Spearman test. A p value <0.05 was
considered to be statistically significant.
3. Results
In the previous study, 24 patients were included. Frozen blood
was available in 20 patients for the present secondary
analysis. There were 2 women and 18 men. Median age was
44 (19–86) years old, median BSA reached 15 (7–85) % and
median ABSI (Abbreviated Burns Severity Index) score was 5
[4–12]. Of the enrolled patients, 8 were discharged before
the end of the protocol. The 12 remaining patients received 7
(2–25) RBC units during the month of follow-up.
Evolution of c-term FGF23 and iFGF23 at each time point for
the 12 patients who completed the study is shown in Fig. 2. The
c-term FGF23 tended to gradually increase during the 4 weeks
of follow-up. However, there was no statistical difference
between concentrations at inclusion and at the end of the
protocol when comparing the 12 patients who completed
the study. iFGF23 was quite more stable into normal ranges.Please cite this article in press as: Rousseau A-F, et al. Fibroblast growth
assay. Burns (2016), http://dx.doi.org/10.1016/j.burns.2016.01.024Iron status is detailed in Table 1. Iron significantly decreased
between D0 and D28 ( p = 0.0078). Ferritin tended to increase at
D28, without reaching significance. Transferrin tended to be
higher at admission than later during hospitalization, again
without reaching significance. Interestingly, the proportions
of normal c-term FGF23 at D0 and D28 were similar to those of
normal iron (Table 2). In the same way, iron concentrations
were negatively correlated to c-term FGF23: the nonparamet-
ric Spearman correlation coefficient (r) was 0.44 (95% CI:
0.71 to 0.05, p = 0.0233). No correlation was found between
c-term FGF23 and ferritin. Contrary to the previously described
correlation between c-term FGF23 and CRP (r = 0.59, 95%
CI:0.22–0.82, p = 0.0032), iFGF23 was not correlated to CRP.
While there was no correlation between iFGF23 and iron,
a negative correlation was found between iFGF23 and ferritin:
r was 0.45 (95% CI: 0.71 to 0.07, p = 0.0179).
At D28, no significant difference was observed between
patients with BSA <20% or patients with BSA 20% regarding
c-term FGF23 and iFGF23. Three of the 12 patients who
completed the study had BSA 40%. When compared to the
nine other patients with lesser injury, c-term or iFGF23 levels
were not statistically different.
Creatinine level was into normal ranges at inclusion and
gradually decreased during the next 4 weeks to reach 6.3 (4.9–
11) mg/l. Phosphate levels remained into normal ranges during
all the protocol (Table 1). Fractional excretion of phosphate
significantly decreased after 28 days. There was no significant
change in 1,25(OH)2-D concentration over the study period.
4. Discussion
FGF23 is a key regulator of phosphate and vitamin D. It is the
subject of a growing research but little is known about its
evolution in the context of burn. We previously highlighted a
positive correlation between c-term FGF23 and CRP. We
presently aimed to complete these data by looking at the
intact portion of the FGF23 protein. Interestingly, c-term FGF23
and iFGF23 did not show a similar evolution following burn.
While c-term FGF23 tended to increase over time and was
positively correlated with CRP, iFGF23 mostly stayed into
normal ranges, without any correlation with the inflammation
marker.
Hypophosphatemia is commonly observed in burn patients
during acute phase [3]. FGF23 is a potent phosphaturic factor
[6]. Based on our previous results showing a progressive
increase in cFGF23 levels after burn, the potential role of FGF23
in burn related hypophosphatemia has been raised. Nonethe-
less, in the present analysis, iFGF23 was not found increased.
This finding now questions our previous assumption. FGF23
cannot be involved in hypophosphatemia if the intact form,
which is the active form, is not increased. This normal intact
form is in line with the results of FE P and 1,25(OH)2-D, that
could not be explained with the only c-term FGF23 values.
In the present study, phosphatemia remained into normal
range due to the regular clinical practice of phosphate
supplementation in case of low phosphate levels. Theoreti-
cally in healthy people, phosphate intakes should lead to an
increase in both c-term and iFGF23, and the increase was
greater for iFGF23 than for the c-term FGF23 [8]. In acute burn factor 23 in acute burn patients: Novel insights from an intact-form
Fig. 2 – Median and ranges (min–max) of c-term FGF23 (a), iFGF23 (b), iron (c) and CRP (d) at admission (D0), day 7 (D7), day 14
(D14), day 21 (D21) and day 28 (D28), for the 12 patients who completed the study. Dotted lines represent normal ranges.
*p < 0.05.
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explained by an increased cleavage of the intact form in the
context of burn. Indeed, literature has recently brought
insights on FGF23 regulation. Gene expression is not the only
process to be regulated: proteolytic cleavage of the mature
FGF23 has now to be considered as the second level of FGF23
regulation [2,7]. Cleavage may be influenced by several factors
or pathological conditions. Among them, some pro-inflam-
matory mediators have recently been confirmed as FGF23
production and cleavage regulators [9]. Iron level is another
described regulator. A trial in women with iron deficiency
confirmed its role in FGF23 regulation, showing elevated levels
of c-term FGF23 but normal iFGF23 concentrations [10]. BurnPlease cite this article in press as: Rousseau A-F, et al. Fibroblast growth
assay. Burns (2016), http://dx.doi.org/10.1016/j.burns.2016.01.024represent a complex condition, resulting in inflammation that
may be systemically extended and that may in turn impact
iron status. Actually, iron levels are known to be low in burn
patients [11], As anticipated, the present data confirmed the
inflammatory status and the low iron levels following burn,
without any influence of RBC transfusions. The increased
cleavage that is suspected in the present burn patients could
be due to inflammation and/or low iron levels. Their respective
roles need to be defined. Likewise, the mechanism of such
regulation is still poorly understood. Very recent animal data
suggest that inflammation stimulates a specific nuclear
transcription factor, the hypoxia-inducible factor 1a (HIF1a).
Secondary to inflammation, functional iron deficiency could in factor 23 in acute burn patients: Novel insights from an intact-form
Table 1 – Lab data at admission (D0), day 7 (D7), day 14 (D14), day 21 (D21) and day 28 (D28). Data are expressed as median
and ranges (min–max). Paired data (at D0 and D28 for the 12 patients who completed the study) were compared using
Wilcoxon test ( p < 0.05 is considered significant). FE P, fractional excretion of phosphate; TSAT, serum transferrin
saturation; CRP, C-reactive protein; NR, normal ranges.
Serum markers NR D0 (n = 20) D7 (n = 18) D14 (n = 16) D21 (n = 13) D28 (n = 12) p value
c-term FGF23 30–176 RU/ml 62.45 (35.7–1363) 85.65 (36.5–4753) 94.3 (28–1321) 89.8 (28.9–2067) 263.7 (63.6–1259) 0.1099
iFGF23 8.6–72.8 pg/ml 24.9 (11.5–93.1) 29.5 (5.6–142) 36 (12.9–154) 32 (12.7–135) 32.45 (8.6–118) 0.3223
Phosphate 0.74–1.51 mmol/l 1.13 (0.49–1.63) 1.06 (0.38–1.37) 1.08 (0.77–1.59) 1.13 (0.55–1.38) 1.05 (0.48–1.64) 0.9097
FE P <20% 12.24 (2.1–31.87) 5.57 (0.99–18.19) 9.05 (0.47–16.6) 14.84 (6.04–32.1) 6.46 (0.47–16.53) 0.0098
1,25(OH)2-D <85 pg/ml 50 (22–78) 42.5 (19–105) 41 (19–69) 31.5 (19–102) 34.5 (19–63) 0.1250
Iron 6–35 mmol/l 13 (4.5–42.1) 3 (1.1–7.7) 4.2 (2.1–22.31) 4.1 (1.2–37.1) 3.9 (2.4–18.2) 0.0078
Ferritin
Male (n = 18) 34–100 mg/l 222.7 (84.6–1683) 564.1 (314.3–1683) 588.9 (155.5–1647) 406.5 (140.7–2886) 632.5 (198.6–1017) 0.7344
Female 15–150 mg/l 1095 (354–1835) 1255 (559.1–1950) 1633 (873.9–2392) 1320 (553.6–2087) 3583 (2576–4589) -
Transferrin 1.6–3.5 g/l 1.9 (1.1–2.5) 1.3 (0.3–1.8) 1.3 (0.5–2.1) 1.3 (0.5–2) 1.3 (0.7–2.1) 0.8438
TSAT 0.2–0.5 0.3 (0.2–0.8) 0.1 (0–0.5) 0.1 (0.1–0.5) 0.2 (0–0.9) 0.1 (0.1–0.4) 0.0078
CRP 0–6 mg/l 3 (0.2–31.3) 147 (16.1–574.4) 102.6 (5.8–254) 80 (14.8–330) 84.6 (9.4–200.4) 0.0005
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both inflammation and low iron levels may possibly act on
FGF23 glycosylation or on proteolytic enzymes, leading to an
increased FGF23 cleavage [12].
No differences were observed about c-term FGF23 or iFGF23
levels between minor burn patients and more severe burn
patients. One could suspect that larger BSA would result in
higher c-term FGF23 levels. This hypothesis should at best be
tested in a further study including a greater number of
patients.
Some limitations need to be considered in the present trial.
First, FGF23 stability after prolonged storage at 808 was not
tested. The potential impact of FGF23 biodegradation on intact
FGF23 levels is unknown. However, storage was under
continuous temperature monitoring and blood samples were
not submitted to repeated thawing. Second, the kidney
function was assessed using blood creatinine levels. It is
now well known that FGF23 increases in case of renal failure.
In CKD patients, both iFGF23 and c-term FGF23 increase with
the progressive loss of renal function [7]. FGF23 changes in
acute kidney injury (AKI) are less obvious, as iFGF23 was not
often measured in the published reports [13]. In such context,
secretion of FGF23 is thought to be increased, associated to a
reduced renal clearance, thus increasing the blood c-term
FGF23 [14]. The only relevant data regarding intact portion
come from a murine model of AKI, in which both c-term FGF23
and iFGF23 increased at 24 hours after injury induction [15].
Blood creatinine level is not a sensitive and specific marker of
kidney function, especially in critical care patients experienc-
ing fluid shifts and muscle catabolism. Cystatin C is probably
a more valid marker in a critical care context [16,17] but it
is not widely available in daily practice. However, using
creatinine levels instead of more accurate strategies doesTable 2 – Numbers and percentages of patients into
normal ranges at D0 and D28.
Lab test D0 D28 p value
c-term FGF23 9/12 (75%) 5/12 (42%) 0.2138
iFGF23 11/12 (92%) 9/12 (75%) 0.5901
Iron 9/12 (75%) 5/12 (42%) 0.2138
Please cite this article in press as: Rousseau A-F, et al. Fibroblast growth
assay. Burns (2016), http://dx.doi.org/10.1016/j.burns.2016.01.024not seem to have influenced results as FGF23 profile in case
of kidney failure differs from the profile reported in the
present study.
Despite the low number of included patients, this study is
the first to focus on intact FGF23 in burn patients. The FGF23
regulation is complex and context dependant. It affects not
only gene expression but also the mature protein cleavage.
From our data, we can postulate that burn is associated with a
disrupt balance between production and cleavage, resulting in
dissociation between c-term FGF23 and iFGF23. The respective
role of inflammation and low iron levels in FGF23 regulation
need to be further explored. In the next future, both c-term
FGF23 and iFGF23 assays will have to be performed when
dealing with patients experiencing inflammatory diseases
such as our model of burn. Ideally, the ratio intact assay/c-
term assay could be a relevant marker of FGF23 bioactivity.
However, to date, values obtained by the two different kits are
difficult to convert. Finally, our results rule out FGF23 as one of
the causes of burn-related hypophosphatemia, as previously
hypothesized.
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